[Lanzoptol efficacy at gastroesophageal reflux disease: results of multicenter study leader].

Abstract

Results of multicenter study "Efficacy of Lansoptol (lansoprazole, KRKA) and its influence on the Dynamics of GERD symptoms" (LIEDER) are presented. The impact of 56-days treatment with lansoprazole 30 mg once daily on symptoms relief, a quality of life of 121 patients with gastroesophageal reflux disease (GERD) and healing of esophageal lesions of 30 patients with reflux esophagitis were investigated. Rapid acid inhibition effect of first dose of lansoptol was shown by 48-hr pH-monitoring. At the first day of the treatment 43.1% of patients reported decreasing of intensity of heartburn and 36.5%--of regurgitation. It were shown that the treatment with lansoptol provided symptoms relief in 25% patients at day 3, in 50% of patients at day 5 and in 75% at day 8 for heartburn, and at days 2, 6 and 9--for regurgitation. It was conducted improvement of quality of life. Healing rate of esophagitis at 28 day was 83.3%.

• Authors: L B Lazebnik, D S Bordin, A A Masharova, E S V'iuchnova, N V Zakharova, R A Abdulkhakov, L V Prokhorova, N N Nikolaeva
• Journal: Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology (Eksp Klin Gastroenterol) Issue 7 Pg. 112-20 ( 2010) ISSN: 1682-8658 [Print] Russia (Federation)
• PMID: 21033092 (Publication Type: Clinical Trial, English Abstract, Journal Article, Multicenter Study)

Chemical References

• 2-Pyridinylmethylsulfinylbenzimidazoles
• Enzyme Inhibitors
• Lansoprazole

Topics

• 2-Pyridinylmethylsulfinylbenzimidazoles (administration & dosage, adverse effects)
• Adult
• Endoscopy, Digestive System
• Enzyme Inhibitors (administration & dosage, adverse effects)
• Female
• Gastroesophageal Reflux (drug therapy, pathology)
• Humans
• Hydrogen-Ion Concentration
• Lansoprazole
• Male
• Middle Aged
• Remission Induction
• Time Factors